目的 探討前列舒通膠囊聯(lián)合普適泰片治療慢性前列腺炎的臨床療效。方法 選取2021年1月—2022年12月如皋市人民醫(yī)院收治的100例慢性前列腺炎患者，根據(jù)計算機隨機排列法將所有患者分為對照組和治療組，每組各50例。對照組飯后口服普適泰片，1片/次，2次/d。治療組在對照組基礎(chǔ)上口服前列舒通膠囊，3粒/次，3次/d。兩組連續(xù)治療3個月。觀察兩組的臨床療效，比較兩組國立衛(wèi)生研究院慢性前列腺炎癥狀指南（NIH-CPSI）評分、最大尿流率、殘余尿量以及血清中總前列腺特異性抗原（TPSA）、白細胞介素-8（IL-8）、白細胞介素-2（IL-2）的水平和前列腺液中白細胞介素-1β（IL-1β）、白細胞介素-6（IL-6）、單核細胞趨化蛋白-1（MCP-1）水平。結(jié)果 治療后，治療組的總有效率92.00%明顯高于對照組的總有效率76.00%，差異有統(tǒng)計學意義（P＜0.05）。治療后，治療組疼痛不適、尿頻尿急、尿不盡消失時間均明顯短于對照組，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組的NIH-CPSI評分低于治療前（P＜0.05），且治療組NIH-CPSI評分較對照組更低（P＜0.05）。治療后，兩組前最大尿流率高于治療前，殘余尿量低于治療前（P＜0.05）；治療后，治療組最大尿流率高于對照組，殘余尿量低于對照組（P＜0.05）。治療后，兩組血清TPSA、IL-8、IL-2水平均低于治療前（P＜0.05）；治療后，治療組患者的血清TPSA、IL-8、IL-2水平低于對照組，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組患者前列腺液IL-1β、IL-6、MCP-1水平低于治療前（P＜0.05）；治療后，治療組患者前列腺液IL-1β、IL-6、MCP-1水平低于對照組（P＜0.05）。結(jié)論 前列舒通膠囊聯(lián)合普適泰片治療慢性前列腺炎的療效確切，可顯著減輕臨床癥狀，控制病情進展，進一步降低炎癥反應(yīng)。

Objective To investigate the clinical effect of Qianlie Shutong Capsules combined with Prostat Tablets in treatment of chronic prostatitis. Methods Patients (100 cases) with chronic prostatitis in the People’s Hospital of Rugao from January 2021 to December 2022 were divided into control group and treatment group according to the computer random arrangement method, and each group had 50 cases. Patients in the control group were po administered with Prostat Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Qianlie Shutong Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and NIH-CPSI scores, maximum urine flow rate, residual urine volume, the serum levels of TPSA, IL-8, and IL-2, the levels of IL-1β, IL-6, and MCP-1 in prostatic fluid of two groups were compared. Results After treatment, the total effective rate of 92.00% in the treatment group was significantly higher than 76.00% in the control group, with statistically significant difference (P< 0.05). After treatment, disappearance time of pain and discomfort, frequent and urgent urination, and inexhaustible urine in the treatment group was lower than those in the control group, with a statistically significant difference (P < 0.05). After treatment, NIH-CPSI scores of two groups were lower than before treatment (P< 0.05), and NIH-CPSI scores of the treatment group were lower than those of the control group (P < 0.05). After treatment, the maximum urine flow rate in two groups was higher than before treatment, but the residual urine volume in two groups was lower than before treatment (P < 0.05). After treatment, the maximum urine flow rate in the treatment group was higher than that in the control group, but the residual urine volume in the treatment group was lower than that in the control group (P < 0.05). After treatment, the serum levels of TPSA, IL-8, and IL-2 in two groups were lower than before treatment (P < 0.05). After treatment, the serum levels of TPSA, IL-8, and IL-2 in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the levels of IL-1β, IL-6, and MCP-1 in the prostatic fluid of two groups were lower than before treatment (P < 0.05). After treatment, the levels of IL-1β, IL-6, and MCP-1 in the prostate fluid of the treatment group were lower than those of the control group (P < 0.05). Conclusion Qianlie Shutong Capsules combined with Prostat Tablets has definite efficacy in treatment of chronic prostatitis, which can significantly reduce clinical symptoms, control the progression of the disease, and further reduce the inflammatory reaction.

R983

江蘇省衛(wèi)生健康委科研課題（H2018091）